Work

439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)

Year: 2020

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.550

Authors: D-Y. Oh, T. Arkenau, K-W. Lee, M. Alsina, F.M. Marti, I.J. Chung, W. Saif, D. Wang, P. O'Dwyer, I. Chau, M-A. Lee, E. Chong, J. Hilger-Rolfe, G. Cole, S.Y. Kim

Institutions: Seoul National University, Seoul National University Hospital, Sarah Cannon Research Institute, Seoul National University Bundang Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, National Health Service, The Christie NHS Foundation Trust, Chonnam National University Hwasun Hospital, Northwell Health, Henry Ford Hospital, University of Pennsylvania, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Pharmacyclics (United States), Asan Medical Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pharmacyclics

OpenAlex ID: W3088809608

FWCI: 0.091

Cites:

Cited by: 2

Related to: 10